Stoke Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STOK research report →
Range $43 – $58
Price Chart
About the company
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States.
- CEO
- Ian F. Smith
- IPO
- 2019
- Employees
- 170
- HQ
- Bedford, MA, US
Get TickerSpark's AI analysis on STOK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.75B
- P/E
- -7.15
- Fwd P/E
- 282.21
- PEG
- -0.04
- P/S
- 62.87
- P/B
- 5.26
- EV/EBITDA
- -6.88
- Div Yield
- 0.00%
- Gross Margin
- 88.52%
- Op Margin
- -913.12%
- Net Margin
- -862.07%
- ROE
- -67.30%
- ROIC
- -72.01%
Latest fiscal year · YoY change
- Revenue
- $184.42M+404.5%
- Gross Profit
- $184.42M+404.5%
- Op Income
- $-20,590,000
- Net Income
- $-6,885,000+92.3%
- EPS
- $-0.12+92.7%
- OCF Growth
- +152.5%
- FCF Growth
- +151.6%
- 52W High
- $40.22
- 52W Low
- $22.05
- 50D MA
- $26.20
- 200D MA
- $30.69
- Beta
- 1.38
- RSI (14)
- 54
- Avg Volume
- 1.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Stoke said EMPEROR is advancing well, the FDA is open to its new Vineland multicomponent plan for zorevunersen, and the company remains on track for a 2027 NDA submission and potential early-2028 U.S. launch.· October 29, 2026
- EMPEROR is progressing with 162 enrolled patients and no treatment discontinuations to date; about 110 patients have reached the week 28 primary endpoint and about 20 have completed week 52.
- The FDA agreed to a multicomponent Vineland-3 approach for the cognition/behavior secondary endpoint in the U.S. NDA, which management said is a positive development for the filing strategy.
- Management reiterated a Q3 2027 data readout and plans to begin submitting NDA data in the first half of 2027, with completion in the second half of 2027.
- The company is building out commercial readiness, including patient support, payer engagement, and site preparation, ahead of a potential early-2028 U.S. launch.
- STK-002 in ADOA is also moving forward, with dosing underway in the third cohort and initial safety/efficacy data expected in the first half of 2027.
Stoke ended the quarter with $358.8 million in cash, cash equivalents, and marketable securities, excluding $3.2 million of restricted cash. Net loss for the 3 months ended September 30 was $73.6 million, including $11 million of noncash stock-based compensation expense. Management said cash, together with reimbursement from Biogen for zorevunersen-related expenses and a potential development milestone payment, is expected to fund operations into early 2028. No revenue figure, EPS, or gross margin was reported on the call. Forward-looking milestones reiterated on the call included a Q3 2027 data readout for EMPEROR, NDA submission in the second half of 2027, and potential U.S. approval in early 2028.
Ian Smith emphasized that the quarter was about advancing zorevunersen toward registration and commercialization while building the organization around a potential U.S. launch. He highlighted the FDA discussion as constructive, especially the agency's willingness to accept a multicomponent Vineland-3 assessment, and said the company is using the time before readout to scale medical affairs, market access, and site readiness. He also framed STK-002 as evidence of Stoke's broader platform opportunity in haploinsufficiency diseases. His tone was confident and operationally focused, with repeated emphasis on progress and preparedness.
Thomas Leggett focused on liquidity and burn, saying Stoke ended the quarter with $358.8 million of cash, cash equivalents, and marketable securities, excluding $3.2 million of restricted cash. He reported a net loss of $73.6 million for the quarter, including $11 million of noncash stock-based compensation expense. He said the company’s priorities remain advancing zorevunersen, preparing for potential U.S. commercialization, and investing in the pipeline while maintaining a strong balance sheet, and that cash plus Biogen reimbursement and a potential milestone payment should fund operations into early 2028. In Q&A, he also guided that Q4 2026 spend should be similar to the Q3 2026 level.
Analysts focused heavily on the new MC4/MC4R Vineland plan, asking about data quality, the role of MMRM, whether the endpoint could succeed if benefit was concentrated in only one or two subdomains, and whether there was any alpha split change. Management said the four Vineland subdomains are weighted equally, there is no hierarchy or alpha split for the secondary endpoint, and the FDA was comfortable reviewing the forest plot to understand drivers of the score. Another major thread was FDA process risk: management said it does not anticipate an advisory committee, expects data submissions in the first half of 2027, and described the 5-year OLE data as a 'review issue' rather than a confirmed label commitment. Questions also covered the background ASM regimen, with management saying patients are kept stable through at least week 28, and ADOA development, where management said the first two cohorts mainly informed safety and the next cohorts move toward therapeutic dosing.
Management appears increasingly confident in zorevunersen’s registrational path, with no discontinuations in EMPEROR, 162 patients enrolled, and FDA alignment on the revised secondary endpoint approach. The commercial and medical infrastructure is being built ahead of launch, and management said payer and provider feedback has been constructive. The company also sees a second asset in STK-002 as advancing through early clinical proof-of-concept, supporting the broader platform story.
The biggest risk remains whether the Phase III data are strong enough at the week 28 and week 52 readouts to support approval, especially since the company is still waiting for the unblinded results. Management also acknowledged that Europe remains more challenging than the U.S. on value assessment, and that the FDA has only said the long-term OLE data would be a 'review issue,' not that it will be included on the label. On the ADOA program, management said the first two cohorts were mainly safety-focused and that it still needs to see whether the higher-dose cohorts produce measurable visual effects.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.1%
- Shares Outstanding
- 65.41M
- Float Shares
- 46.50M
of shares held by institutions
203 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.35M | ▲ 470.47K |
| Rtw Investments, LP | 5.62M | 0 |
| Fmr LLC | 5.00M | ▼ 312.15K |
| Lynx1 Capital Management LP | 4.04M | ▼ 725.27K |
| Redmile Group, LLC | 3.95M | ▼ 218.20K |
| Wellington Management Group Llp | 3.52M | ▲ 423.60K |
| Baker Bros. Advisors LP | 3.34M | 0 |
| Morgan Stanley | 3.21M | ▼ 242.46K |
| Toronto Dominion Bank | 3.17M | 0 |
| Vanguard Group Inc | 3.15M | ▼ 14.63K |
| Vanguard Capital Management LLC | 2.73M | ▲ 146.48K |
| Price T Rowe Associates Inc | 2.66M | ▲ 727.57K |
Held by 330 ETFs
Biggest fund positions in STOK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Ticho Barry | sell | 6,995 |
| Nov 2, 26 | Ticho Barry | sell | 200 |
| Oct 2, 26 | Allan Jonathan | sell | 627 |
| Oct 1, 26 | Ticho Barry | sell | 1,051 |
| Sep 23, 26 | Cumbo Alexander | other | 39,674 |
| Sep 23, 26 | Cumbo Alexander | other | 0 |
| Sep 1, 26 | Ticho Barry | sell | 3,945 |
| Sep 1, 26 | Ticho Barry | sell | 1,600 |
| Aug 14, 26 | Ticho Barry | other | 10,000 |
| Aug 18, 26 | Ticho Barry | sell | 4,525 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STOK coverage
Recent articles, reports, and earnings notes.
No research on STOK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STOK report →Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com · Nov 17
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 30
Stoke Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Oct 29
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 29
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
businesswire.com · Oct 29
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
gurufocus.com · Oct 22
Stoke Therapeutics: The Market Misread A Key FDA Win
seekingalpha.com · Oct 19
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
businesswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.